Navigation Links
Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
Date:3/23/2009

breast cancer. In this trial, patients with high levels of EpCAM expression, in a dose-dependent fashion, developed significantly less new lesions as compared to patients with low levels of EpCAM (2).

"Numerous published clinical and preclinical data suggest that therapies targeting EpCAM such as adecatumumab could prove to be highly effective anti-cancer therapeutics," commented Carsten Reinhardt, MD, Chief Medical Officer of Micromet. "We look forward to exploring the promise of adecatumumab to eliminate minimal residual disease in colorectal cancer patients and thereby to potentially improve cure rates in these patients at high risk of relapse."

Colorectal cancer is the third most common cancer in western countries with more than 145,000 new cases diagnosed in the US each year. About 25 percent of patients present with liver metastases at first diagnosis, and an additional 35 to 45 percent of patients will develop metastases during the course of their disease. The only chance of long-term survival comes with curative resection of hepatic metastasis by liver surgery with reported five and 10 year survival rates of 41 percent and 22 percent, respectively. Previous trials of combination chemotherapy regimens in these patients have demonstrated only very modest improvements in survival. Even intensified treatment regimens, such as the one recently published EORTC Intergroup trial 40983, which compared peri-operative FOLFOX plus surgery to surgery alone, demonstrated only 7% improvement in progression free survival at three years (3).

References

1) Maetzel D. et al., Nature Cell Biology 2009; 11: 162-171

2) Dittrich C. et al., AACR-NCI-EORTC meeting 2007

3) Nordlinger et al., Lancet 2008; 371: 1007

About Micromet

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Key Events for 2009
2. Micromet Expands Committed Equity Financing Facility to $75 Million
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
7. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
8. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
11. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Second Quarter 2015 Investor Conference Call and ... The call will cover an update on ... quarter 2015 financials. A press release detailing the information ... the afternoon of Monday, August 10. Investors and the ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, Inc., ... its second clinical development program with a Phase ... CL-H1T contains fast-dissolving promethazine and ... as a treatment for migraine headache pain and ... "Many patients with migraine headaches also suffer from ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China ... CSKI ), a leading fully integrated pharmaceutical company in ... shareholder letter from Mr. Yanqing Liu, the Company,s Chairman ... full text of this shareholder letter is as follows: ...
... 21, 2011 VIVUS, Inc. (Nasdaq: VVUS ) ... Food and Drug Administration (FDA) for the New Drug Application ... obesity.  The meeting occurred on January 19th at the FDA,s ... the FDA and VIVUS, management and consultants.  At this meeting ...
Cached Medicine Technology:Shareholder Letter from Chairman of China Sky One Medical 2Shareholder Letter from Chairman of China Sky One Medical 3Shareholder Letter from Chairman of China Sky One Medical 4VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los ... in need. Most people know that general health emergencies, such as broken arms or ... of people know where to turn to during a dental emergency. This is important, ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show ... Fifty-five percent of respondents said they agreed or strongly agreed that the controversial ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
(Date:8/3/2015)... ... 2015 , ... Illinois Health & Science (IHS) has completed the purchase of ... all of IBAM NA’s cyclotron sites and research and development facilities. , ... as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Government Programs, with accountability for overall performance of the company’s Medicare and Federal ... focus of Cambia’s strategy to deliver better health for members. In this role, ...
Breaking Medicine News(10 mins):Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... chapping, experts advise , SATURDAY, Dec. 26 (HealthDay News) ... humidity, and the air inside is heated and dry, you ... say. , To prevent scaling, flaking and itching, pay special ... a cream-based moisturizer every day, recommends Dr. Anjali Dahiya, a ...
... Christmas trees and holiday distractions raise risk of a blaze ... on beautifully set tables and yule logs burning make for ... the risk of fires, experts say. , Alcohol and parties ... safety, said Dr. Roger Yurt, director of the Hearst Burn ...
... to those in pot that increase the response to sweets ... some light on the "munchies" -- the desire that pot ... the active ingredient in marijuana, is similar to substances known ... and enhance the perception of sweet foods, researchers say. , ...
... Mouse study holds promise for humans with hereditary disease ... reporting that they,ve discovered a molecular switch that appears ... in mice. , An estimated one out of every ... and disrupts a person,s ability to walk, talk, think ...
... , WASHINGTON, Dec. 24 This ... final passage of HR 3590, the so-called "Patient Protection and ... Research Council President Tony Perkins made the following comments: , ... debate in the Senate, but it,s far from the end ...
... Bill Must Be Improved: Anti-Choice Provisions in Senate and House ... Affordable , WASHINGTON, Dec. 24 The following ... for Women & Families: , "The Senate took a historic ... morning by passing comprehensive reform that will cover 31 million ...
Cached Medicine News:Health News:Skin Needs Protection From Winter Weather 2Health News:Keep Fire Safety in Mind as You Celebrate 2Health News:Scientists Find Molecular Switch Related to Huntington's 2Health News:FRC Statement on the Christmas Eve Passage of the Health Care 'Reform' Bill 2Health News:Senate Passage of Health Reform a Historic Milestone, National Partnership President Says 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: